Immediate Impact

3 by Nobel laureates 4 from Science/Nature 65 standout
Sub-graph 1 of 21

Citing Papers

Renal cell carcinoma
2024 Standout
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
2023 Standout
1 intermediate paper

Works of Mark R. Olsen being referenced

PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer
2013
Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma
2012

Author Peers

Author Last Decade Papers Cites
Mark R. Olsen 579 410 254 20 757
Ursula Vogl 410 392 336 20 864
Kristina Lamberg 412 402 191 20 762
Sven Gogov 399 335 287 25 768
H. Depenbrock 491 569 234 33 923
Tim Eisen 602 296 524 29 883
Ilaria Imarisio 459 306 332 37 908
Erin Larkins 418 608 271 26 881
Robin Wiltshire 702 546 284 17 803
Daniel Lee 587 484 185 34 794
Joyce Cheng 354 570 231 28 893

All Works

Loading papers...

Rankless by CCL
2026